^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Astrocytoma
    Drug:PLX4720 (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

    Excerpt:
    We found significant therapeutic benefit of PLX4720 monotherapy against murine 10776 astrocytoma...Similarly, PD0332991 monotherapy provided a significant benefit...
    DOI:
    10.1073/pnas.1117255109
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Targeted Therapy for BRAFV600E Malignant Astrocytoma

    Excerpt:
    Using orthotopic MA xenografts, we demonstrate that PLX4720 treatment decreases tumor growth and increases overall survival in mice bearing BRAFV600E mutant xenografts, while being ineffective, and possibly tumor promoting, against xenografts with wild-type BRAF.
    DOI:
    10.1158/1078-0432.CCR-11-1456